Albemarle (NYSE:ALB) PT Lowered to $205.00 at Deutsche Bank Aktiengesellschaft

Enanta Pharmaceuticals (NASDAQ:ENTA – Get Rating) had its target price reduced by research analysts at HC Wainwright from $68.00 to $48.00 in a report released on Tuesday, The Fly reports. HC Wainwright’s price objective points to a potential upside of 81.06% from the stock’s current price. Several other analysts also recently weighed in on the […]

Related Keywords

Piper Sandler ,Paulj Mellett ,Institutional Trading Of Enanta Pharmaceuticals ,Enanta Pharmaceuticals Company Profile ,Enanta Pharmaceuticals Inc ,Enanta Pharmaceuticals ,Jpmorgan Chase Co ,Norges Bank ,Enanta Pharmaceuticals Stock Performance ,News Ratings For Enanta Pharmaceuticals Daily ,Analyst Recommendations For Enanta Pharmaceuticals ,Get Rating ,Street Corp ,Asset Management ,Enanta Pharmaceuticals Daily ,Nasdaq Enta ,Enta ,Medical ,Lower Price Target ,Hc Wainwright ,